A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection
Clinical trial NCT05407519 · UNKNOWN
Trial details
- NCT number
- NCT05407519
- Sponsor
- Anhui Provincial Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-25
- Primary completion
- 2026-06-30
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.